Abzena's John Burt 'very pleased' to close Taiwanese biopharma Thiobridge deal

Jul 13, 2017, 10:22 AM

John Burt, chief executive of Abzena plc (LON:ABZA) tells Proactive they've inked an agreement with a Taiwanese biopharmaceutical company worth up to £128mln to license out its ThioBridge technology.

ThioBridge is an antibody drug conjugate (ADC) linker, which in layman’s terms means it attaches antibodies and other proteins to drugs.